Dental Care Clinics in Harriman, NY Accepting Medicare
4 Dental Care Clinics found. Showing 1 - 4
 Woodbury Family Dental, Pllc Dentist Medicare: Not Enrolled in Medicare Practice Location: 118 River Rd, Suite 14, Harriman, NY 10926 Phone: 845-782-1800 Fax: 845-782-3116 |
Manish Patel Orthodontist, Pc Dentist - Orthodontics and Dentofacial Orthopedics Medicare: Not Enrolled in Medicare Practice Location: 33 Ny-17m, Suite E, Harriman, NY 10926 Phone: 845-774-2724 |
Harriman Family Dental Dentist Medicare: Not Enrolled in Medicare Practice Location: 96 Route 17m, Harriman, NY 10926 Phone: 845-783-6466 Fax: 845-783-6468 |
Woodbury Family Dental Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 118 River Road, Suite # 14, Harriman, NY 10926 Phone: 845-782-1800 Fax: 845-782-3116 |
News Archive
Gilead Sciences signs definitive agreement to acquire CGI Pharmaceuticals
Gilead Sciences, Inc. and CGI Pharmaceuticals, Inc., a privately-held, development-stage pharmaceutical company focused on small molecule chemistry and kinase biology, today announced the signing of a definitive agreement pursuant to which Gilead will acquire CGI. Under the terms of the agreement, Gilead will acquire CGI for up to $120 million, the majority as an upfront payment and the remaining based on clinical development progress, all of which will be financed through available cash on hand.
Adipose hormone levels may be independent risk factor for obesity-related asthma
New research suggests a hormone released from fat tissue is critical in the development of obesity-related asthma and may be a target of future treatments for the disease. The findings will be presented Saturday, March 23 at ENDO 2019, the Endocrine Society's annual meeting in New Orleans, La.
NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa, and South America.
sigma-tau Group acquires Enzon's specialty pharmaceutical business
Enzon Pharmaceuticals, Inc. ("Enzon") announced today that it has closed the sale of its specialty pharmaceutical business to the sigma-tau Group ("sigma-tau"). Enzon is a biopharmaceutical company dedicated to the discovery and development of important medicines for patients with cancer and other life-threatening conditions. Enzon's business now consists of its royalties, Peg SN38, LNA and PEG technology platforms.
› Verified 3 days ago